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Abstract
Introduction and hypothesis Previous studies aiming to iden-
tify specific pre-defined urine protein biomarkers for stress
urinary incontinence (SUI) have not identified clinically im-
portant differences. The hypothesis of our study was that the
global distribution of urinary proteins, the proteome, differs
between women with and those without SUI.
Methods In this age-matched case–control study, we com-
pared the urinary proteome of 20 women with SUI and 20
controls. Proteins were identified by applying high-
performance liquid chromatography separation and tandem
mass spectrometry detection. Data analysis was performed
using Mascot 2.4.1 embedded in ProteinScape 3.1.
Results We identified 828 different proteins. The concentra-
tion of six of those showed a significant difference between
urine samples of SUI patients and those of controls (q val-
ue<0.25). Four proteins showed a higher abundance in SUI
samples compared with controls: plasma serine protease in-
hibitor (logFC 1.11), leucine-rich alpha-2-glycoprotein
(logFC 3.91), lysosomal alpha-glucosidase (logFC 1.24),
and peptidyl-prolyl cis- trans isomerase A (logFC 1.96). We
identified two proteins in lower abundance in SUI samples
compared with controls: uromodulin (logFC −4.87) and
TALPID3 (logFC −1.99).
Conclusions Overexpression of plasma serine protease inhib-
itor, leucine-rich alpha-2-glycoprotein, lysosomal alpha-glu-
cosidase, and peptidyl-prolyl cis- trans isomerase A, and low-
er expression of uromodulin and TALPID3, in urine may be
associated with female SUI.
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Introduction
Stress urinary incontinence (SUI) is defined as the complaint
of Binvoluntary loss of urine on effort or physical exertion
including sporting activities, or on sneezing or coughing^
[1]. It has a widely varying estimated prevalence of 15–
77 % of the female population. SUI represents both a psycho-
logical and an economic burden, and prevalence rates are ex-
pected to increase in the future, because of increasing life
expectancy [2–5]. The classical epidemiology of SUI is well
understood, with many environmental and life style risk fac-
tors identified, including age, obesity, parity, vaginal delivery,
and family history [6–12]. Still, much of the etiology of SUI
remains unclear, and it is difficult to predict which women are
at risk.
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Proteomics research offers one strategy to elucidate the
etiology of SUI by identification of a significant and sufficient
number of proteins, which provides the ability to avoid a pre-
selection of candidate proteins. Many different serum, urine,
and/or tissue protein markers have been investigated in the
context of SUI. Almost all studies have targeted specific pro-
teins as putative biomarkers, but with negative results.
Previous studies have investigated the role of serum C-
reactive protein [13], serum relaxin [14], and serum estradiol
[15], without finding significant associations with symptoms.
To our knowledge, no study has yet investigated the com-
plete urinary proteomic profile associated with SUI.
We aimed to determine a possible altered urinary protein
profile in women suffering from SUI compared with healthy
women, with the overall goal of providing new insights into
the pathophysiology.
Materials and methods
This was a prospective case–control study using proteomic
analysis of urine samples from patients with SUI and healthy
age-matched controls. Ethics approval was obtained from the
ethics committee of the Medical University of Vienna
(1788/2013). This trial was registered with ClinicalTrials.
gov (NCT02023502).
The study was conducted between October 2013 and
June 2015 as a cooperative project among the Department of
Obstetrics and Gynecology, the Clinical Division of
Urogynecology, and the Proteomics Core Facility, Medical
University of Vienna. The inclusion criteria for stress inconti-
nence cases were: a history of symptoms of SUI for at least
3 months (including a specific history of the complaint of
involuntary leakage on effort or exertion or on sneezing or
coughing), a positive provocation stress test (defined as an
observed transurethral loss of urine simultaneous with a cough
or Valsalva maneuver at a bladder volume of 300 ml), nega-
tive urine dipstick testing, age≥18 years, patients capable of
independent toileting, written informed consent, and at least
one previous vaginal delivery. Exclusion criteria were: previ-
ous treatment for SUI (surgical or pharmacological), a history
of overactive bladder symptoms and/or urinary incontinence
other than SUI (tested using the ICIQ short form question-
naire) [16]; neurological disorders potentially affecting the
urinary tract system, such as multiple sclerosis, Parkinson’s
disease; pelvic organ prolapse stage ≥ II (International
Continence Society classification), clinically significant blad-
der out le t obstruct ion and/or post void residual
volume>100 ml; a history of acute urinary retention or a
history of repeated catheterizations, a history of bladder can-
cer or previous surgery to the urinary tract; acute or recurrent
urinary tract infection and/or hematuria; a history of urinary
tract stones; renal insufficiency and/or hepatic disease; a
history of alcohol and/or drug abuse; pregnancy or lactation;
and finally any patient with a serious medical condition.
Participants in the control group met identical criteria, but with
no symptomatic SUI (ICIQ short form score equal to zero),
and a negative cough stress test. Urine samples were obtained
once only without requirement for a specific time of day.
Participants were given a sterile urine cup (maximum 50 ml)
and asked to deliver the first-void urine. In addition, we re-
trieved blood samples from the peripheral veins of all partic-
ipants to determine their creatinine, transaminase, and biliru-
bin status. Urine samples were stored in the refrigerator at 4 °C
for a maximum of 1 h before being taken to the Clinical
Institute of Laboratory Medicine (Proteomics Core Facility)
for immediate processing.
Protein precipitation was performed by one of the authors
according to the internally modified Wessel–Flüge method of
protein precipitation and all solvents were kept at −20 °C. All
working steps were performed on ice and centrifugation in a
cooled centrifuge at +4 °C. Two ml of each urine sample were
mixed with 6 ml methanol and 2 ml dichloromethane in a 50-
ml Falcon tube and samples were vigorously vortexed. After
adding 6 ml of water to each sample, solutions were vortexed
again. Samples were subsequently stored at −20 °C for a min-
imum of 20 min for enhancement of protein precipitation.
Phase separation was carried out by subsequent centrifugation
for 5 min at 4,500 rounds per minute (rpm). The upper layer of
the solution was then carefully discarded while keeping the
interphase and lower layer, and an additional 6 ml of methanol
were added before vigorous vortexing. Final centrifugation
was performed for 5 min. The resulting supernatant was care-
fully removed and the remaining protein pellet was dried in
the air. The dried protein pellet was later dissolved in 200 μl of
50 mM triethylammonium bicarbonate at pH 8.5 (TEAB). In
cases where the protein pellet could not be properly dissolved
in 200 μl of 50 mM TEAB, an additional 50–1,000 μl of
50 mM TEAB were added and the sample was sonicated by
using the ultrasonic cell disruptor (Ultrasonic Cell Disruptor;
Branson, Dietzenbach, Germany). Bradford protein assay was
used to determine the protein concentration within the solution
(mg/ml). The following protein digestion was performed as
described by Mitulović et al. [17]. Briefly, disulfide bonds
were reduced by the addition of dithiothreitol (DTT; 10 μg
protein: 0.1 μg DTT) and incubation at 56 °C for 30 min.
Alkylation of reduced proteins was performed by the addition
of iodacetamide (IAA; 10 μg protein: 0.5 μg IAA) and incu-
bation in darkness for 20 min at ambient temperatures. Upon
reduction and alkylation, DTT was added to neutralize the
excess of IAA and enable tryptic digestion, where sequence
grade-modified trypsin (Promega, Mannheim, Germany;
1:10) was added to the sample, followed by overnight incu-
bation at 37 °C. Tryptic digest was stopped by the addition of
trifluoroacetic acid to a final concentration of 10 %. Upon
tryptic digest, 30 μl of tryptic peptides were diluted with
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20 μl of aqueous 0.1%TFA and 10 μl of sample were injected
undiluted onto the chromatographic column. Peptide separa-
tions were performed using an Ultimate 3000 nano RSLC sep-
aration system (Thermo Fisher Scientific, Germering,
Germany) coupled to the maXis Impact qToF mass spectrom-
eter equipped with the captive spray electrospray source
(Bruker, Bremen, Germany). The captive spray source was
modified and a stainless steel needle (20 μm ID x 105 mm;
Thermo Fisher Scientific, Vienna, Austria) was used instead of
the default silica capillary for sample ionization, at 1.8 kV, and
the source temperature was set to 150 °C. Samples were loaded
onto a C18 trap column (300 μm ID x 5 mmAcclaim PepMap,
5-μm particle size, 100-Å pore size) using cooled (5 °C) aque-
ous 0.1%TFA at 30 μl/min as a loading mobile phase, and
separated on a C18 nano separation column (75 μm ID x
250mmAcclaim PepMap, 3-μmparticle size, 100-Å pore size)
operated at the flow rate of 300 nl/min. The gradient for nano-
HPLC separation of tryptic peptides was generated using the
following mobile phases: 5% acetonitrile (AcN) in 0.1 % aque-
ous formic acid (FA) and 0.08 % FA in 50 % AcN, 30 %
methanol, 10 % trifluoroethanol (TFE), 0.08 % FA.
All masses with a signal higher than 5,000 counts were
submitted for fragmentation (MS/MS). MS/MS fragmentation
was performed by applying a cycle time of 3 s, single charged
peptides were excluded from fragmentation, and active exclu-
sion was used for fragmented masses for 2 min. All MS/MS
spectra were transformed into .mgf files for data analysis by
applying an internal script from Data Analysis 4.1 (Bruker).
Data analysis was performed using Mascot 2.4.1 (Matrix
Science, London, UK) embedded in ProteinScape 3.1
(Bruker). Search parameters were as follows: the latest version
of the IPI_human decoy database was used, trypsin was se-
lected as the digestion enzyme, and two miscleavages were
allowed. Monoisotopic peptide masses were searched with
50-ppm peptide mass tolerance and 0.5-Da fragment mass
tolerance. The large mass tolerance for the database search
was selected, although the actual mass accuracy of the data
analyzed was <5 ppm. Carbamidomethyl on Cys was selected
as a fixed modification and oxidation on Met as the variable
peptide modification. Matches with Mascot scores >15, two
peptides per protein, and a significance threshold of p<0.05
were considered positive hits.
The sample size was planned as 20 patients per group
(n=40; false discovery rate 0.05, power 80 %, assumed pro-
portion of true null hypotheses 0.95, and assumed standard-
ized effect size 1; based on two-sample paired t test) and
patients were matched for age (± 5 years). Similarities to tag
count-based mRNA technologies led us to employ an
overdispersed Poisson model combined with empirical
Bayes methods, as commonly used to estimate mRNA tag
abundance. Count data were loaded into R (version 3.1.3)
and protein abundance was estimated by calculating peptide
counts normalized to counts per million (cpm). Log2-fold
change was estimated based on variance stabilized average
log2 cpm values using the package edgeR. [18]. Resulting p
values were corrected for multiple testing according to Bass
[19]. A q value of <0.25 was considered statistically
significant.
Statistical analysis of demographic data was computed ap-
plying independent t test for scaled variables (age, BMI, ICIQ
score, number of vaginal deliveries) and Chi-squared test for
nominal variables (status of menopause, presence of chronic
disease).
The manuscript was structured according to the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guidelines (for observational stud-
ies) and to the Minimum Information About A Proteomics
Experiment (MIAPE) (for proteomic research).
Results
One urine sample was retrieved from each participant (cases
n=20; controls n=20) and included in the final analysis (total
n=40). Demographic data were similar in the case and control
group (Table 1). We identified 6,415 proteins in the control
group and 5,310 in the case group when identifications with
one peptide per protein were included and identifications from
all samples were taken into account. However, only proteins
with at least two detected and identified peptides were selected
for further statistical analysis. Thus, 828 individual proteins
were entered into the statistical analysis.
Six of the 828 proteins showed a significant difference in
abundance in urine samples between SUI and controls (q
value<0.25; Table 2). Four proteins showed a higher abundance
in SUI samples compared with controls: plasma serine protease
inhibitor (logFC 1.11), leucine-rich alpha-2-glycoprotein
(logFC 3.91), lysosomal alpha-glucosidase (logFC 1.24), and
peptidyl-prolyl cis- trans isomerase A (logFC 1.96). Two pro-
teins (gene symbol: UMOD; gene symbol: KIAA0586) present-
ed a lower abundance in SUI samples compared with controls:
uromodulin (logFC −4.87) and TALPID3 (logFC −1.99).
Discussion
This pilot study identified six putative SUI-specific urinary
proteins, to our knowledge for the first time.
Plasma serine protease inhibitor (SERPINA5), leucine-rich
alpha-2-glycoprotein (LRG1), lysosomal alpha-glucosidase
(GAA) and peptidyl-prolyl cis-trans isomerase A (PPIA) were
more highly expressed in urine samples from women with SUI.
Plasma serine protease inhibitor (SERPINA5) is usually present
in urine in very low concentrations and serves, among other
functions, as a pro-inflammatory factor. Recent publications re-
garding diverse medical conditions, including pediatric
Int Urogynecol J (2016) 27:1729–1734 1731
leukemia, breast cancer, HIV infection, and hepatocellular carci-
noma have identified the role of SERPINA5 [20–23]. Leucine-
rich alpha-2-glycoprotein, a secreted protein normally present in
plasma, is involved in nonspecific inflammatory and cancer pro-
cesses. It has recently been described in the context of ulcerative
colitis activity, invasive bladder cancer, biliary tract cancer, lung
cancer, pancreatic cancer, heart failure, neutrophilic granulocyte
differentiation, and autoimmune diseases [24].
Lysosomal alpha-glucosidase (GAA) is a protein essential
for the degradation of glycogen to glucose in lysosomes,
which is present in all tissue cell types. Mutations in the re-
spective gene result in Pompe disease, a condition in which a
lack of lysosomal alpha-glucosidase leads to the
intralysosomal accumulation of glycogen, which consequent-
ly disables heart and skeletal muscles. The protein has also
been identified as a potential biomarker for gut wall integrity
in infants with necrotizing enterocolitis, an inflammatory pro-
cess involving intestinal tissue [25].
Peptidyl-prolyl cis-trans isomerase A is involved in inflam-
matory processes/immunomodulation and induction of
interleukin-6 release from macrophages. Recent publications
have discussed an involvement in type II diabetes mellitus,
vascular disease, and gastric adenocarcinoma [26].
The proteins uromodulin and TALPID3 had lower expres-
sion in SUI samples. Among other functions, uromodulin is
involved in the prevention of urinary tract infection, water/
electrolyte balance, and kidney innate immunity, and is usu-
ally highly abundant in the urine of healthy humans [27].
TALPID3 is required for ciliogenesis and sonic hedgehog/
SHH signaling [28].
We do not imply to have found biomarkers for SUI, but
rather a group of proteins with a significantly different abun-
dance in SUI patients compared with controls. By investigat-
ing the known functions, tissue specificities and interactions
of the specific proteins, we may be able to gain insight into the
potential mechanisms of the pathophysiology and etiology of
SUI. Proteins that were identified with significantly higher
abundance in SUI samples, are described as being involved
in inflammatory processes and cancer development, whereas
those with a significantly lower abundance usually seem to
have a protective effect in the urinary tract system.
The strengths of this study include that urine samples were
retrieved from a population with very strict inclusion and exclu-
sion criteria to avoid confounding factors. Demographic data
showed that there was no significant difference between the case
and control group regarding BMI, age, and parity (Table 1).
Table 1 Demographic data of
patients with stress urinary
incontinence (SUI) versus
controls
Patients with SUI (n= 20) Controls (n= 20) p value
Age (years), mean (± SD) 49 (±9) 49 (±10) 0.961
BMI (kg/m2), mean (± SD) 28 (±6) 25 (±5) 0.119
ICIQ sum score, mean (± SD) 13 (±4) 0 (0) 0.000
Vaginal deliveries, n mean (± SD) 2.1 (±0.9) 1.9 (±0.7) 0.462
Chronic diseases, n (%)a 10/20 (50) 11/20 (55) 0.752
Menopause, n (%) 0.501
Premenopausal 15/20 (75) 12/20 (60)
Postmenopausal 5/20 (25) 8/20 (40)
ICIQ-UI short form International Consultation on Incontinence Modular Questionnaire
a Number of patients with chronic diseases (including hypertension, coronary heart disease, colitis, depression,
gastritis, diabetes type II, glaucoma, chronic atrial fibrillation, asthma, Hashimoto thyroiditis, hyperthyroidism,
tricuspidal valve insufficiency, factor V Leiden)
Table 2 Proteins with a
significantly different abundance
in the urine of patients with SUI
compared with controls
Protein Accession Gene symbol logFC q value
Tax_Id=9606 Gene_Symbol=SERPINA5
plasma serine protease inhibitor
IPI00007221 SERPINA5 1.111 0.029
Tax_Id=9606 Gene_Symbol=LRG1
leucine-rich alpha-2-glycoprotein
IPI01012772 LRG1 3.909 0.019
Tax_Id=9606 Gene_Symbol=GAA
lysosomal alpha-glucosidase
IPI00293088 GAA 1.237 0.062
Tax_Id = 9606 Gene_Symbol=UMOD uromodulin IPI00640271 UMOD −4.867 0.002
Tax_Id=9606 Gene_Symbol=PPIA
peptidyl-prolyl cis-trans isomerase A
IPI00910407 PPIA 1.962 0.227
Tax_Id=9606 Gene_Symbol=KIAA0586 TALPID3 IPI01010584 KIAA0586 −1.992 0.227
logFC logarithm of expression 1 (cases) minus the logarithm of expression 2 (controls) to basis 2 (log2(Exp1)-
log2(Exp2)=logFC)
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Urine samples were processed according to a standardized pro-
tocol within a very short time frame after collection (maximum
1 h). Moreover, all steps of sample processing were consecu-
tively executed by two of the authors, which reduces a potential
inter-observer bias and provides consistency in sample handling.
Whereas previous studies on SUI have tested serum and/or uri-
nary proteins as potential biomarkers for SUI, there has been no
other study, to our knowledge, that has aimed to compare the
complete urinary proteome of patients with SUI with that of
healthy controls. Preceding studies have targeted specific pro-
teins suspected to play a role in the development of SUI (e.g.,
serum C-reactive protein, relaxin, estrogen, etc.) [14, 15].
By applying liquid chromatography and mass spectrome-
try, we were able to possibly identify a significant and suffi-
cient number of proteins present in one urine sample, which
provides the ability to avoid a pre-selection of candidate pro-
teins. The main limitation of this study is that we only re-
trieved and investigated one urine sample per patient.
Therefore, we cannot avoid the bias that the urinary proteome
potentially changes in one individual dependent on, for exam-
ple, daytime, food intake, method of retrieval, etc. However,
there is no guideline for urine sample collection regarding
subsequent proteomic analysis and little is known about cir-
cadian urinary proteome changes or external influences.
Another limitation is the incomplete Bhumane proteome
mapping.^ Despite the efforts of the research community to
identify and characterize all human proteins, this project has
not yet been completed. Therefore, it is possible to identify
proteins that have not yet been characterized, but which are
hypothesized as products of specific genes owing to the sim-
ilarity of their peptide chains to known proteins.
Last, by investigating the urinary proteome only at one
time point, we cannot draw a conclusion on whether the sig-
nificantly differently expressed proteins are a consequence of
the pathological process, or whether they themselves are di-
rectly involved in causal processes.
The relevance of these results regarding the pathogenesis of
SUI, focusing on protein interactions, needs to be more broad-
ly investigated and the results of this pilot study need to be
replicated in a different population.
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